Healthcare products company West Pharmaceutical Services (NYSE: WST) will be announcing earnings results tomorrow before market open. Here’s what to expect.

West Pharmaceutical Services beat analysts’ revenue expectations last quarter, reporting revenues of $844.9 million, up 21% year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting West Pharmaceutical Services’s revenue to grow 9.9% year on year, in line with the 9.2% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. West Pharmaceutical Services rarely misses Wall Street’s revenue estimates.

With West Pharmaceutical Services being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for life sciences tools & services stocks. However, there has been positive investor sentiment in the segment, with share prices up 9.3% on average over the last month. West Pharmaceutical Services is up 8.2% during the same time .

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.